Results 51 to 60 of about 1,413 (82)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Nature Medicine, 2023
Manish A Shah, Kohei Shitara, Jaffer A Ajani   +2 more
exaly  

Coordinated TCP Westwood congestion control for multiple paths over wireless networks

The International Conference on Information Network 2012, 2012
T. Le, C. Hong, Eui-nam Huh
semanticscholar   +1 more source

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

Efficiency/friendliness tradeoffs in TCP Westwood

Proceedings ISCC 2002 Seventh International Symposium on Computers and Communications, 2002
Ren Wang, Massimo Valla, M. Sanadidi, Bryan C H Kwok, Fai Ng, M. Gerla   +5 more
semanticscholar   +1 more source

ANALISIS KINERJA TCP WESTWOOD UNTUK PENCEGAHAN KONGESTI PADA JARINGAN LTE DENGAN MENGGUNAKAN NETWORK SIMULATOR 2.33 (NS2.33)

, 2014
G. Permatasari, S. Sukiswo, Imam Santoso
semanticscholar   +1 more source

Adaptive bandwidth share estimation in TCP Westwood

Global Telecommunications Conference, 2002. GLOBECOM '02. IEEE, 2002
Ren Wang, Massimo Valla, M. Sanadidi, M. Gerla   +3 more
semanticscholar   +1 more source

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Nature Medicine, 2022
, Ewa Kalinka-Warzocha, Ruben G W Quek
exaly  

Fluid-flow analysis of TCP Westwood with RED

GLOBECOM '03. IEEE Global Telecommunications Conference (IEEE Cat. No.03CH37489), 2003
Jiwei Chen, F. Paganini, M. Sanadidi, Ren Wang, M. Gerla   +4 more
semanticscholar   +1 more source

TCP Westwood: analytic model and performance evaluation

GLOBECOM'01. IEEE Global Telecommunications Conference (Cat. No.01CH37270), 2001
A. Zanella, G. Procissi, M. Gerla, M. Sanadidi   +3 more
semanticscholar   +1 more source

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nature Medicine, 2021
Ken Kato, Yoshito Komatsu, Satoshi Yuki
exaly